TABLE 1.
Patient Characteristics
| All included |
BR after RP only* |
BR after RT only* |
||||
| Variable | Data | n | Data | n | Data | n |
| Age (y) | 69.1 ± 6.5 | 130 | 68.4 ± 6.3 | 92 | 70.8 ± 6.9 | 35 |
| Body weight (kg) | 87.4 ± 14.4 | 130 | 86.9 ± 14.4 | 92 | 87.7 ± 13.5 | 35 |
| Height (cm) | 177.3 ± 6.8 | 130 | 176.9 ± 6.8 | 92 | 177.5 ± 6.6 | 35 |
| Injected activity (MBq) | 369.2 ± 47.2 | 130 | 367.8 ± 47.1 | 92 | 371.1 ± 46.0 | 35 |
| Uptake time (min) | 120.4 ± 1.5 | 130 | 120.5 ± 1.7 | 92 | 120.2 ± 0.6 | 35 |
| Inclusion criteria† | ||||||
| Known PC after radical prostatectomy with BR | 94 (72.3%) | 130 | 92 (100%) | 92 | 0 (0.0%) | 35 |
| Known PC after radiation therapy with BR | 37 (28.5%) | 130 | 0 (0.0%) | 92 | 35 (100%) | 35 |
| PSA at baseline (ng/mL) | 5.20 ± 6.50 | 130 | 3.03 ± 3.40 | 92 | 11.11 ± 8.94 | 35 |
| PSA doubling time (mo) | 12.2 ± 11.8 | 113 | 12.0 ± 12.3 | 78 | 12.9 ± 11.1 | 32 |
| Treatment history† | ||||||
| Surgery | 94 (72.3%) | 130 | 92 (100%) | 92 | 0 (0.0%) | 35 |
| Radiotherapy† | 45 (34.6%) | 130 | 7 (7.6%) | 92 | 35 (100%) | 35 |
| Brachytherapy | 27 (60.0%) | 45 | 0 (0.0%) | 7 | 26 (74.3%) | 35 |
| External-beam therapy | 20 (44.4%) | 45 | 5 (71.4%) | 7 | 13 (37.1%) | 35 |
| Intensity-modulated radiation therapy | 4 (8.9%) | 45 | 2 (28.6%) | 7 | 2 (5.7%) | 35 |
| Proton therapy | 1 (2.2%) | 45 | 0 (0.0%) | 7 | 1 (2.9%) | 35 |
| 223RaCl2 | 0 (0.0%) | 45 | 0 (0.0%) | 7 | 0 (0.0%) | 35 |
| Androgen-deprivation therapy | 62 (47.7%) | 130 | 39 (42.4%) | 92 | 22 (62.9%) | 35 |
| Chemotherapy | 1 (0.8%) | 130 | 1 (1.1%) | 92 | 0 (0.0%) | 35 |
*
Inclusion criteria.
†
Categories are not mutually exclusive.
PC = prostate cancer; BR= biochemical recurrence; RP = radical prostatectomy; RT = radiation therapy.
Data are mean ± SD or proportions.